Eli Lilly to invest US$3B in expanding Wisconsin manufacturing facility

USA—Eli Lilly has announced plans to invest US$3 billion to expand its recently acquired manufacturing facility in Kenosha County, Wisconsin.

This expansion is a strategic step to strengthen the company’s global parenteral product manufacturing network and meet the growing demand for its diabetes and obesity treatments, as well as future pipeline products in other therapeutic areas.  

The project, slated to begin construction in 2025, will create 750 skilled jobs, including roles for operators, technicians, engineers, and scientists. 

This will add to the current workforce of over 100 employees, while the construction phase alone is expected to generate more than 2,000 jobs. 

The expanded facility will focus on producing injectable medicines and assembling and packaging medical devices for various therapeutic uses.  

To enhance efficiency and product quality, Eli Lilly will incorporate advanced automation technologies, including robotics and guided vehicles. 

Digital automation will also play a critical role in improving precision and speed, allowing staff to prioritize the production of safe, high-quality medicines.  

This investment is part of Lilly’s broader strategy to bolster its manufacturing capabilities worldwide. 

Since 2020, the company has committed US$23 billion to new constructions, facility expansions, and acquisitions.

 Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, noted, “This is our single largest U.S. manufacturing investment outside Indiana. We’re excited to bring high-paying, advanced jobs to Wisconsin, which is becoming a key location for our global operations.” 

Cambrex to support Lilly’s Catalyze360-ExploR&D Program

In related development, Lilly has partnered with Cambrex, a contract development and manufacturing organization, to accelerate clinical development for Lilly’s biotech collaborators. 

Cambrex will support Lilly’s early innovation program, Catalyze360-ExploR&D, by providing drug substances, products, analytical services, and R&D expertise.  

Most of Cambrex’s services will be delivered from its Longmont, Colorado facility, which specializes in early drug development, including both non-GMP and cGMP production. 

The Longmont site also offers formulation development and comprehensive analytical testing. 

This collaboration aims to advance scientific discovery and expedite the development of promising new medicines, aligning with Lilly’s commitment to innovation and patient care.  

These developments underline Eli Lilly’s dedication to expanding its manufacturing capabilities and fostering innovation, ensuring it meets the evolving needs of patients worldwide. 

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.